BioTuesdays

Category - Markets

Arrowhead Pharmaceuticals
Markets

WB ups Arrowhead to OP

William Blair upgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “outperform” from “market perform” and raised its fair value estimate to $6 from $2 after the company’s R&D day on Sept. 14. The stock closed at $3...

September 18, 2017
Tactile Systems Technology
Markets

BTIG cuts Tactile Systems to neutral

BTIG downgraded Tactile Systems Technology (NASDAQ:TCMD) to “neutral” from “buy,” saying the stock is up more than 100% year-to-date, exceeding its price target of $35. The stock closed at $36.79 on Sept. 15. Tactile...

September 18, 2017
Applied Genetic
Markets

HCW cuts Applied Genetic price target to $8

H.C. Wainwright slashed its price target for Applied Genetic Technologies (NASDAQ:AGTC) to $8 from $16 but maintained its “buy” rating after the company posted financing results below consensus for the fiscal year ended...

September 13, 2017
Sientra Logo
Markets

WB ups Sientra to OP

William Blair upgraded Sientra (NASDAQ:SIEN) to “outperform” from “market perform,” saying the company’s corporate strategy should begin to pay off over the next six-to-18 months. Sientra is a medical aesthetics company...

September 13, 2017
Collegium Pharma
Markets

HCW starts Collegium at buy

H.C. Wainwright initiated coverage of Collegium Pharmaceuticals (NASDAQ:COLL) with a “buy” rating and $21 price target. The stock closed at $10.21 on Sept. 8. Collegium is a leading player in the abuse-deterrent...

September 11, 2017
NewLink Genetics
Markets

Stifel ups NewLink price target to $29

Stifel raised its price target for NewLink Genetics (NASDAQ:NLNK) to $29 from $14 after the company on the weekend updated Phase 2 data in patients with advanced melanoma. The stock closed at $17.67 on Sept. 8. In a...

September 11, 2017
NeoGenomics
Markets

BTIG cuts NeoGenomics to neutral

BTIG downgraded NeoGenomics (NASDAQ:NEO) to “neutral” from “buy,” citing hurricanes that have hit Texas and Florida and noting that the shares are near its $11 price target, almost reaching an all-time high. The stock...

September 11, 2017
Flex Pharma
Markets

Roth restarts Flex Pharma at buy

Roth Capital Partners reinitiated coverage of Flex Pharma (NASAQ:FLKS) with a “buy” rating and $14 price target. The stock closed at $3.37 on Sept. 6. Flex is developing FLX-787, an innovative anti-cramp drug in...

September 7, 2017
Verastem
Markets

HCW ups Verastem price target to $10

H.C. Wainwright raised its price target for Verastem (NASDAQ:VSTM) to $10 from $6.50 after the company reported positive top-line results from a Phase DUO study of duvelisib for the treatment of relapsed/refractory...

September 7, 2017
theralase logo
Markets

Echelon starts Theralase at speculative buy

Echelon Wealth Partners initiated coverage of Theralase Technologies (TSXV:TLT) with a “speculative buy” rating and one-year price target of 90 cents. The stock closed at 47 cents on Sept. 1. Analyst Doug Loe writes...

September 5, 2017